Department of Urology, The First Hospital of China Medical University, Shenyang, 110001, China.
Department of Gynecology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, China.
J Exp Clin Cancer Res. 2023 Mar 28;42(1):72. doi: 10.1186/s13046-023-02625-0.
Although the aberrant activation of NOTCH1 pathway causes a malignant progression of renal cell carcinoma (RCC), the precise molecular mechanisms behind the potential action of pro-oncogenic NOTCH1/HES1 axis remain elusive. Here, we examined the role of tumor suppressive miR-138-2 in the regulation of NOTCH1-HES1-mediated promotion of RCC.
This study employed bioinformatics, xenotransplant mouse models, ChIP assay, luciferase reporter assay, functional experiments, real-time PCR and Western blot analysis to explore the mechanisms of miR-138-2 in the regulation of NOTCH1-HES1-mediated promotion of RCC, and further explored miR-138-2-containing combination treatment strategies.
There existed a positive correlation between down-regulation of miR-138 and the aberrant augmentation of NOTCH1/HES1 regulatory axis. Mechanistically, HES1 directly bound to miR-138-2 promoter region and thereby attenuated the transcription of miR-138-5p as well as miR-138-2-3p. Further analysis revealed that miR-138-5p as well as miR-138-2-3p synergistically impairs pro-oncogenic NOTCH1 pathway through the direct targeting of APH1A, MAML1 and NOTCH1.
Collectively, our current study strongly suggests that miR-138-2 acts as a novel epigenetic regulator of pro-oncogenic NOTCH1 pathway, and that the potential feedback regulatory loop composed of HES1, miR-138-2 and NOTCH1 contributes to the malignant development of RCC. From the clinical point of view, this feedback regulatory loop might be a promising therapeutic target to treat the patients with RCC.
尽管 NOTCH1 通路的异常激活导致肾细胞癌(RCC)的恶性进展,但潜在的致癌 NOTCH1/HES1 轴的精确分子机制仍不清楚。在这里,我们研究了肿瘤抑制 miR-138-2 在调节 NOTCH1-HES1 介导的促进 RCC 中的作用。
本研究采用生物信息学、异种移植小鼠模型、染色质免疫沉淀(ChIP)检测、荧光素酶报告基因检测、功能实验、实时 PCR 和 Western blot 分析等方法,探讨了 miR-138-2 调节 NOTCH1-HES1 介导的 RCC 促进作用的机制,并进一步探讨了 miR-138-2 包含的联合治疗策略。
miR-138 的下调与 NOTCH1/HES1 调节轴的异常增强之间存在正相关。在机制上,HES1 直接结合 miR-138-2 启动子区域,从而减弱 miR-138-5p 和 miR-138-2-3p 的转录。进一步分析表明,miR-138-5p 和 miR-138-2-3p 通过直接靶向 APH1A、MAML1 和 NOTCH1,协同损害致癌的 NOTCH1 通路。
综上所述,我们的研究强烈表明,miR-138-2 是致癌性 NOTCH1 通路的一种新型表观遗传调节剂,由 HES1、miR-138-2 和 NOTCH1 组成的潜在反馈调节环有助于 RCC 的恶性发展。从临床角度来看,该反馈调节环可能是治疗 RCC 患者的有前途的治疗靶点。